Emergent BioSolutions awarded five grants totalling $1.2 million under QTDP Program

Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded five separate grants under the Qualifying Therapeutic Discovery Project (QTDP) Program to support continued development of its therapeutic programs in oncology and autoimmunity. The grants, with a total value of over $1.2 million, will fund Emergent's TRU-016 Small Modular ImmunoPharmaceutical (SMIP™), DRACO anti-CD3 SMIP, X1 TNF-based SCORPION™, X2 CTLA4-based SCORPION, and T-Scorps-based SCORPION therapeutic programs.

"Emergent's product development efforts in oncology and autoimmunity continue to further candidates that could have the potential to improve disease outcomes and patient quality of life," said Dr. W. James Jackson, chief scientific officer of Emergent BioSolutions. "We are pleased that the U.S. government has recognized our efforts through these grant awards."

The QTDP Program was established by Congress as part of recent health legislation reform and is designed to foster biotechnology growth and innovation. The program also seeks to create and sustain biotechnology jobs in the U.S. To be an eligible recipient, a company must adequately demonstrate that it is working on therapeutic projects that:

• Result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions,
• Reduce the long-term growth of healthcare costs in the U.S., or
• Significantly advance the goal of curing cancer within 30 years.